A similar retrospective analysis of patients with MDS or AML who received azacytidine therapy suggested that the DNMT3A mutation was associated with better response rates only if TET2 and IDH1/2 mutations co-existed [81]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.